ArticleGenome biology2019
Multiplexed promoterless gene expression with CRISPReader.
Article in Genome biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 26 citations in OpenAlex.
- Reprogramming the tumor microenvironment with c-MYC-based gene circuit platform to enhance specific cancer immunotherapy.Nature communications · 2025Article
- Advancements in genetic circuits as part of intelligent biotherapy for the treatment of bladder cancer: A review.Bladder (San Francisco, Calif.) · 2025Review
- CRISPR-based gene expression platform for precise regulation of bladder cancer.Cellular & molecular biology letters · 2024Article
- Synthetic biology approaches for improving the specificity and efficacy of cancer immunotherapy.Cellular & molecular immunology · 2024Review
- CRISPR-based molecule-regulatory expression platform for specific immunotherapy of cancer.Frontiers in oncology · 2024Article
- Advances in Recombinant Adeno-Associated Virus Vectors for Neurodegenerative Diseases.Biomedicines · 2023Review
- Building Blocks of Artificial CRISPR-Based Systems beyond Nucleases.International journal of molecular sciences · 2022Review
- CRISPR signal conductor 2.0 for redirecting cellular information flow.Cell discovery · 2022Article
- CRISPR/Cas systems: Delivery and application in gene therapy.Frontiers in bioengineering and biotechnology · 2022Review
- CRISPReader System Sensing the Ets-1 Transcription Factor Can Effectively Identify Cancer Cells.Frontiers in molecular biosciences · 2021Article
- Synthesizing AND gate minigene circuits based on CRISPReader for identification of bladder cancer cells.Nature communications · 2020Article
- Improving transgene expression and CRISPR-Cas9 efficiency with molecular engineering-based molecules.Clinical and translational medicine · 2020Article
- Recent advances of genome editing and related technologies in China.Gene therapy · 2020Review
- CRISPR-Based Synthetic Transcription Factors In Vivo: The Future of Therapeutic Cellular Programming.Cell systems · 2020Review
- Genome Editing for CNS Disorders.Frontiers in neuroscience · 2020Review
- CRISPR/Cas9-related technologies in liver diseases: from feasibility to future diversity.International journal of biological sciences · 2020Review
- RNAi-mediated control of CRISPR functions.Theranostics · 2020Article
- Engineering Cellular Signal Sensors based on CRISPR-sgRNA Reconstruction Approaches.International journal of biological sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGenes are comprised of DNA codes and contain promoters and other control elements for reading these codes. The rapid development of clustered regularly interspaced short palindromic repeats (CRISPR) technology has made possible the construction of a novel code-reading system with low dependency on the native control elements.
resultsWe develop CRISPReader, a technology for controlling promoterless gene expression in a robust fashion. We demonstrate that this tool is highly efficient in controlling transcription and translation initiation of a targeted transgene. A notable feature of CRISPReader is the ability to "read" the open reading frames of a cluster of gene without traditional regulatory elements or other cofactors. In particular, we use this strategy to construct an all-in-one AAV-CRISPR-Cas9 system by removing promoter-like elements from the expression cassette to resolve the existing AAV packaging size problem. The compact AAV-CRISPR-Cas9 is also more efficient in transactivation, DNA cleavage, and gene editing than the dual-AAV vector encoding two separate Cas9 elements, shown by targeting both reporter and endogenous genes in vitro and in vivo.
conclusionsCRISPReader represents a novel approach for gene regulation that enables minimal gene constructs to be expressed and can be used in potential biomedical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.